PRESS RELEASE published on 01/11/2024 at 18:00, 1 year 10 months ago BioGX Expands PCR Test Menu at State Departments of Health BioGX, a leading provider of molecular diagnostic solutions, has announced the expansion of its test menu to support state Departments of Health with the addition of its Candida auris assay. This expansion will provide access to BioGX's molecular assays designed for speed, precision, and reliability, empowering healthcare professionals with the best tools available to improve public health outcomes. Healthcare Professionals BioGX Molecular Diagnostic Solutions Candida Auris Assay Public Health
PRESS RELEASE published on 07/24/2023 at 06:00, 2 years 4 months ago BioGX Candida Auris PCR Assay Global Adoption Accelerates
PRESS RELEASE published on 03/23/2023 at 19:00, 2 years 8 months ago BioGX Candida Auris PCR Assay Adoption Accelerates
PRESS RELEASE published on 02/28/2023 at 21:00, 2 years 9 months ago BioGX Ships First Batch of pixl(TM) Real-Time PCR Platform to US Laboratories
Published on 12/05/2025 at 02:35, 4 hours 4 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 39 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 34 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 39 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 8 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 48 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 13 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 24 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 28 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 24 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 39 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 39 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 54 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 54 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
